Article
Cardiac & Cardiovascular Systems
Yogesh N. Reddy, Barry A. Borlaug, Bernard J. Gersh
Summary: Atrial fibrillation is the most common arrhythmia in heart failure patients and can be both the cause and consequence of clinical heart failure. Some patients may benefit from maintaining sinus rhythm with catheter ablation. There is a close relationship between atrial fibrillation, left atrial myopathy, mitral regurgitation, and heart failure with preserved ejection fraction, with potential clinical benefits to catheter ablation therapy. Treatment of atrial fibrillation also requires consideration of the degree of atrial myopathy and chronicity of atrial fibrillation.
Article
Cardiac & Cardiovascular Systems
Maura M. Zylla, Johannes Leiner, Ann-Kathrin Rahm, Tobias Hoffmann, Patrick Lugenbiel, Patrick Schweizer, Eberhard Scholz, Derliz Mereles, Dorothea Kronsteiner, Meinhard Kieser, Hugo A. Katus, Norbert Frey, Dierk Thomas
Summary: This study evaluates the outcome of cryoballoon ablation for atrial fibrillation in patients with heart failure with preserved ejection fraction (HFpEF). The results show that patients with HFpEF have a higher risk of atrial fibrillation recurrence and heart failure-related hospitalization after ablation. There is limited improvement in cardiac function and quality of life in these patients.
CIRCULATION-HEART FAILURE
(2022)
Article
Cardiac & Cardiovascular Systems
Toru Kondo, Azmil H. Abdul-Rahim, Atefeh Talebi, William T. Abraham, Akshay S. Desai, Kenneth Dickstein, Silvio E. Inzucchi, Lars Kober, Mikhail N. Kosiborod, Felipe A. Martinez, Milton Packer, Mark Petrie, Piotr Ponikowski, Jean L. Rouleau, Marc S. Sabatine, Karl Swedberg, Michael R. Zile, Scott D. Solomon, Pardeep S. Jhund, John J. McMurray
Summary: A simple risk model can be used to identify HFrEF patients without AF who have a high risk of stroke, allowing for targeted use of prophylactic anticoagulant therapy.
EUROPEAN HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Jawad H. Butt, Toru Kondo, Pardeep S. Jhund, Josep Comin-Colet, Rudolf A. de Boer, Akshai S. Desai, Adrian F. Hernandez, Silvio E. Inzucchi, Stefan P. Janssens, Mikhail N. Kosiborod, Carolyn S. P. Lam, Anna Maria Langkilde, Daniel Lindholm, Felipe Martinez, Magnus Petersson, Sanjiv J. Shah, Jorge Thierer, Muthiah Vaduganathan, Subodh Verma, Ulrica Wilderang, Brian C. Claggett, Scott D. Solomon, John J. V. McMurray
Summary: This study examined the effects of dapagliflozin in patients with atrial fibrillation (AF) and found that its benefits were consistent across different types of AF.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Review
Medicine, General & Internal
Laurent Fauchier, Arnaud Bisson, Alexandre Bodin
Summary: Atrial fibrillation (AF) and heart failure (HF) are often associated with each other and can worsen each other's condition. Recent trials have shown that treatment with SGLT2 inhibitors can reduce the risk of worsening heart failure or cardiovascular death in patients with HFpEF, regardless of whether they have AF or not. Early rhythm-control therapy and catheter ablation have also been proven effective in improving outcomes for patients with AF and HF. Therefore, a holistic and integrated care management approach following the ABC pathway is crucial for patients with AF and HFpEF.
Article
Cardiac & Cardiovascular Systems
Gerasimos Filippatos, Dimitrios Farmakis, Javed Butler, Faiez Zannad, Joao Pedro Ferreira, Anne Pernille Ofstad, Tomoko Iwata, Martina Brueckmann, Stuart J. Pocock, Milton Packer, Stefan D. Anker
Summary: This study aimed to assess the efficacy and safety of empagliflozin in patients with HF and LVEF >40% with and without AF. The results showed that empagliflozin improved outcomes in terms of heart failure events and renal function, regardless of the presence of baseline AF. There was no increase in adverse events with empagliflozin compared to placebo.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Medicine, General & Internal
Ruxandra-Nicoleta Horodinschi, Camelia Cristina Diaconu
Summary: This study analyzed diastolic dysfunction in patients with heart failure (HF) and atrial fibrillation (AF) depending on left ventricle ejection fraction (LVEF). The results showed that patients with HF with reduced ejection fraction (HFrEF) and AF had more severe diastolic dysfunction and higher left ventricular filling pressures compared to those with HF with preserved ejection fraction (HFpEF) and AF.
Article
Cardiac & Cardiovascular Systems
Yu-Sheng Lin, Jeng-Yu Jan, Jung-Jung Chang, Ming-Shyan Lin, Teng-Yao Yang, Po-Chang Wang, Mien-Cheng Chen
Summary: This study aimed to evaluate the effect of ivabradine in HFrEF patients with paroxysmal AF, and the results showed that ivabradine treatment was associated with an increased risk of HF hospitalization.
Article
Cardiac & Cardiovascular Systems
Ravi B. Patel, Vivek Y. Reddy, Jan Komtebedde, Stephan W. Wegerich, Jadranka Sekaric, Vijay Swarup, Antony Walton, Gabriel Laurent, Stanley Chetcuti, Matthias Rademann, Martin Bergmann, Scott McKenzie, Heiko Bugger, Raphael Romano Bruno, Howard C. Herrmann, Ajith Nair, Deepak K. Gupta, Scott Lim, Samir Kapadia, Robert Gordon, Marc Vanderheyden, Thomas Noel, Steven Bailey, Zachary M. Gertz, Jean-Noel Trochu, Donald E. Cutlip, Martin B. Leon, Scott D. Solomon, Dirk J. van Veldhuisen, Angelo Auricchio, Sanjiv J. Shah
Summary: Nearly 40% of patients with HFpEF and HFmrEF have subclinical AF within 1 year. Baseline AF burden, even at low levels, is associated with HF events. Atrial shunt therapy does not affect AF incidence or burden.
JACC-HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Toru Kondo, Karola S. Jering, Pardeep S. Jhund, Inder S. Anand, Akshay S. Desai, Carolyn S. P. Lam, Aldo P. Maggioni, Felipe A. Martinez, Milton Packer, Mark C. Petrie, Marc A. Pfeffer, Margaret M. Redfield, Jean L. Rouleau, Dirk J. van Veldhuisen, Faiez Zannad, Michael R. Zile, Scott D. Solomon, John J. V. McMurray
Summary: This study validated a simple risk model for predicting stroke risk in heart failure patients with preserved ejection fraction but without atrial fibrillation. The results showed that the risk for stroke increased with increasing risk score, suggesting the use of anticoagulation therapy in high-risk patients.
CIRCULATION-HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Maja Cikes, Ivo Planinc, Brian Claggett, Jonathan Cunningham, Davor Milicic, Nancy Sweitzer, Michele Senni, Mauro Gori, Gerard Linssen, Sanjiv J. Shah, Milton Packer, Marc Pfeffer, Michael R. Zile, Inder Anand, Lu-May Chiang, Carolyn S. P. Lam, Margaret Redfield, Akshay S. Desai, John J. V. McMurray, Scott D. Solomon
Summary: The study found that a history of AFF and presence of AFF at enrollment were associated with a higher risk of adverse outcomes in HFpEF patients. Additionally, first-detected AFF was not influenced by sacubitril/valsartan treatment, but was linked to increased risk of subsequent outcomes.
JACC-HEART FAILURE
(2022)
Article
Cardiac & Cardiovascular Systems
Lin Bai, Yuxi Sun, Jiping Si, Zijie Ding, Xinxin Zhang, Yanli Zhang, Yunlong Xia, Ying Liu
Summary: Rhythm-control therapy can reverse left atrial structure remodeling and improve clinical outcomes, making it an optimal treatment approach for patients with atrial fibrillation and heart failure with preserved ejection fraction (HFpEF).
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Charles D. Nicoli, Wesley T. O'Neal, Emily B. Levitan, Matthew J. Singleton, Suzanne E. Judd, George Howard, Monika M. Safford, Elsayed Z. Soliman
Summary: The study established associations between atrial fibrillation and both reduced and preserved ejection fraction heart failure, with no significant difference in the strength of association among these subtypes.
Article
Cardiac & Cardiovascular Systems
John Gierula, Charlotte A. Cole, Michael Drozd, Judith E. Lowry, Sam Straw, Thomas A. Slater, Maria F. Paton, Rowenna J. Byrom, Ellis Garland, Georgia Halliday, Sarah Winsor, Gemma K. Lyall, Karen Birch, Melanie McGinlay, Emma Sunley, Peter J. Grant, David H. Wessels, Elias M. Ketiar, Klaus K. Witte, Richard M. Cubbon, Mark T. Kearney
Summary: This study aimed to compare the risk of progressive heart failure death and hospitalization between patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The results showed that patients with de novo HFrEF had a higher risk of death or hospitalization due to progressive heart failure compared to patients with HFpEF. Atrial fibrillation (AF) was the only marker associated with an increased risk of progressive heart failure death or hospitalization in HFpEF patients, suggesting it may be a potential therapeutic target in this population.
Article
Cardiac & Cardiovascular Systems
Jesse D. Cochran, Yoshimitsu Yura, Mark C. Thel, Heather Doviak, Ariel H. Polizio, Yuka Arai, Yohei Arai, Keita Horitani, Eunbee Park, Nicholas W. Chavkin, Anupreet Kour, Soichi Sano, Nitin Mahajan, Megan Evans, Mahalia Huba, Nadia Martinez Naya, Hanna Sun, Young Ho Ban, Karen K. Hirschi, Stefano Toldo, Antonio Abbate, Todd E. Druley, Frederick L. Ruberg, Mathew S. Maurer, Justin A. Ezekowitz, Jason R. B. Dyck, Kenneth Walsh
Summary: The study identified an enrichment of TET2-mediated CH in patients with HFpEF, which was associated with exacerbated diastolic dysfunction. Patients with HFpEF, aged >= 70 years and CH, exhibited a worse prognosis in terms of 5-year cardiovascular-related hospitalization rate compared with those without CH.
Article
Cardiac & Cardiovascular Systems
Mark C. Petrie, Pardeep S. Jhund, Eugene Connolly, Patrick B. Mark, Michael R. MacDonald, Michele Robertson, Stefan D. Anker, Sunil Bhandari, Kenneth Farrington, Philip A. Kalra, David C. Wheeler, Charles R. Tomson, Ian Ford, John J. McMurray, Iain C. Macdougall
Summary: This study aimed to investigate the effect of high-dose vs. low-dose intravenous iron on myocardial infarction in patients on maintenance haemodialysis. The results showed that high-dose IV iron reduced myocardial infraction in patients receiving haemodialysis.
CARDIOVASCULAR RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Kieran F. Docherty, John J. V. McMurray, Brian L. Claggett, Zi Michael Miao, Kirkwood F. Adams, Alexandra Arias-Mendoza, John G. F. Cleland, Rafael Diaz, Luis E. Echeverria Correa, G. Michael Felker, Candida Fonseca, Jing Li, Marco Metra, Karen Sliwa-Hahnle, Scott D. Solomon, Hans J. Vandekerckhove, Dragos Vinereanu, Adriaan A. Voors, Stephen B. Heitner, Stuart Kupfer, Fady I. Malik, Lisa Meng, John R. Teerlink
Summary: This study aimed to examine the effect of omecamtiv mecarbil in heart failure patients according to the NT-proBNP levels. The results showed that omecamtiv mecarbil had a greater benefit in patients with higher baseline NT-proBNP levels, especially those without atrial fibrillation/flutter.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Robert J. H. Miller, Derek S. Chew, Lei Qin, Nowell M. Fine, Jieling Chen, John J. V. McMurray, Jonathan G. Howlett, Phil McEwan
Summary: This study compares the cost-effectiveness of immediate and 12-month delayed initiation of dapagliflozin treatment in patients with a history of hospitalization for heart failure from different healthcare perspectives. Using a decision-analytic Markov model, the study found that immediate initiation of dapagliflozin reduces heart failure events and cardiovascular mortality. Immediate initiation of dapagliflozin provides greater clinical benefits and should be considered standard of care.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Review
Cardiac & Cardiovascular Systems
James P. Curtain, Matthew M. Y. Lee, John J. McMurray, Roy S. Gardner, Mark C. Petrie, Pardeep S. Jhund
Summary: In this meta-analysis, we examined the efficacy of implantable haemodynamic monitoring (IHM)-guided care in patients with heart failure (HF). The results showed that IHM-guided care reduced HF hospitalisations and worsening HF events across all ejection fraction (EF) ranges. However, the effect of IHM-guided care on worsening HF events in patients with HFpEF (EF >= 50%) was uncertain and further studies are needed.
Letter
Cardiac & Cardiovascular Systems
Jawad H. Butt, Scott D. Solomon, John J. V. McMurray
Article
Cardiac & Cardiovascular Systems
Leanne Mooney, Colette E. Jackson, Carly Adamson, Alex McConnachie, Paul Welsh, Rachel C. Myles, John J. V. McMurray, Pardeep S. Jhund, Mark C. Petrie, Ninian N. Lang
Summary: Circulating levels of interleukin-6 may identify patients at greater risk of adverse outcomes following hospitalization with heart failure with preserved ejection fraction.
CIRCULATION-HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Karola S. Jering, Brian L. Claggett, Marc A. Pfeffer, Christopher B. Granger, Lars Kober, Eldrin F. Lewis, Aldo P. Maggioni, Douglas L. Mann, John J. V. McMurray, Margaret F. Prescott, Jean L. Rouleau, Scott D. Solomon, Phillippe Gabriel Steg, Dirk von Lewinski, Eugene Braunwald
Summary: NT-proBNP is an important prognostic factor in patients with acute myocardial infarction and certain risk factors. It is associated with heart failure, death, and atherosclerotic events, and this predictive information is independent of hs-cTnT.
CIRCULATION-HEART FAILURE
(2023)
Review
Cardiac & Cardiovascular Systems
Ewa A. Jankowska, Tomas Andersson, Claudia Kaiser-Albers, Biykem Bozkurt, Ovidiu Chioncel, Andrew J. S. Coats, Loreena Hill, Friedrich Koehler, Lars H. Lund, Theresa McDonagh, Marco Metra, Clemens Mittmann, Wilfried Mullens, Uwe Siebert, Scott D. Solomon, Maurizio Volterrani, John J. V. McMurray
Summary: Despite the rapid development of therapies and tools for heart failure (HF), everyday management in clinical practice remains suboptimal. A workshop convened by the European Society of Cardiology (ESC) identified barriers, such as the complexity of HF and its treatment, financial constraints, failure to meet patient needs, suboptimal outpatient management, and fragmented healthcare systems. Ongoing initiatives and proposed actions aim to address these barriers and improve patient outcomes.
Article
Cardiac & Cardiovascular Systems
Toru Kondo, Xiaowen Wang, Mingming Yang, Pardeep S. Jhund, Brian L. Claggett, Muthiah Vaduganathan, Adrian F. Hernandez, Carolyn S. P. Lam, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Mikhail N. Kosiborod, Akshay S. Desai, Lars Kober, Piotr Ponikowski, Marc S. Sabatine, Anna Maria Langkilde, Magnus Petersson, Natalia Zaozerska, Erasmus Bachus, Scott D. Solomon, John J. V. Mcmurray
Summary: The efficacy and safety of dapagliflozin were consistent across global regions despite geographic differences in patient characteristics, background treatment, and event rates.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Shingo Matsumoto, Toru Kondo, Pardeep S. Jhund, Ross T. Campbell, Karl Swedberg, Dirk J. van Veldhuisen, Stuart J. Pocock, Bertram Pitt, Faiez Zannad, John J. V. McMurray
Summary: This study evaluated the safety and efficacy of eplerenone according to the duration of heart failure with reduced ejection fraction (HFrEF). The results showed that the benefits of eplerenone were consistent regardless of HFrEF duration, with the longest-duration group experiencing the greatest absolute benefit.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Urology & Nephrology
Robert A. Fletcher, Niels Jongs, Glenn M. Chertow, John J. V. Mcmurray, Clare Arnott, Meg J. Jardine, Kenneth W. Mahaffey, Vlado Perkovic, Patrick Rockenschaub, Peter Rossing, Ricardo Correa-Rotter, Robert D. Toto, Muthiah Vaduganathan, David C. Wheeler, Hiddo J. L. Heerspink, Brendon L. Neuen
Summary: This study analyzed the effect of SGLT2 inhibitors on the discontinuation of RAS blockade and found that patients receiving SGLT2 inhibitors had a lower risk of discontinuing RAS blockade. This effect was particularly pronounced in patients with a high baseline urinary albumin-to-creatinine ratio.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Review
Cardiac & Cardiovascular Systems
Matthew M. Y. Lee, Toru Kondo, Ross T. Campbell, Mark C. Petrie, Naveed Sattar, Scott D. Solomon, Muthiah Vaduganathan, Pardeep S. Jhund, John J. Mcmurray
Summary: This meta-analysis evaluates the safety and efficacy of renin-angiotensin system (RAS) blockers in the treatment of COVID-19. The results suggest that ACE inhibitors and ARBs can be continued in non-severe patients, but initiation of RAS blockers may be harmful in critically ill patients.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
Joanna Osmanska, Katriona Brooksbank, Kieran F. Docherty, Stacy Robertson, Kirsty Wetherall, Alex McConnachie, Jerry Hu, Roy S. Gardner, Andrew L. Clark, Iain B. Squire, Paul R. Kalra, Pardeep S. Jhund, Pieter Muntendam, John J. McMurray, Mark C. Petrie, Ross T. Campbell
Summary: This study compared the bioavailability, pharmacokinetic and pharmacodynamic profiles between subcutaneous and intravenous furosemide, and described the use of a mini-pump for subcutaneous administration. The results showed that subcutaneous furosemide had similar bioavailability to intravenous furosemide, and administration via a patch pump was feasible and well tolerated.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
John Ostrominski, B. Claggett, M. Packer, M. Pfeffer, C. Lam, M. Zile, A. Desai, P. Jhund, M. Lefkowitz, J. Mcmurray, S. Solomon, M. Vaduganathan
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Meeting Abstract
Endocrinology & Metabolism
M. Vaduganathan, S. E. Inzucchi, B. L. Claggett, I. Kulac, R. A. de Boer, A. S. Desai, K. F. Docherty, A. F. Hernandez, M. N. Kosiborod, P. S. Jhund, C. S. P. Lam, F. A. Martinez, S. J. Shah, J. J. V. McMurray, S. D. Solomon